Abstract 70P
Background
PD-1 blockade combined with chemotherapy has become the standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without oncogenic drivers. Oncogenic-driven advanced NSCLC showed limited response to PD-1 blockade monotherapy or chemotherapy alone. Whether NSCLC patients with oncogenic drivers showed response to PD-1 blockade plus chemotherapy remains undetermined.
Methods
329 patients with at least one oncogenic driver alteration NSCLC receiving PD-1 plus chemotherapy or each monotherapy were retrospectively identified. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were used to evaluate the therapeutic outcomes differences among patients with different oncogenic drivers.
Results
Totally, 176 patients received PD-1 blockade plus chemotherapy, 60 patients received PD-1 blockade monotherapy and 93 patients received chemotherapy alone were included. Oncogenic drivers including KRAS (31.0%), EGFR (30.4%), HER2 (14.6%), BRAF (10.3%), RET (7.0%) and other mutations (6.7%) were identified. Compared with PD-1 and chemo mono-treatment, patients with oncogenic drivers received PD-1 blockade plus chemotherapy showed significantly better objective response rate (48% vs 22% and 26%; P < 0.001), progression-free survival (median 9.5 vs 3.8 and 5.6 months; P < 0.001) and overall survival (median 25.3 vs 16.8 and 17.0 months; P < 0.001). Multivariate cox regression analysis revealed that PD-1 blockade plus chemotherapy showed dramatically improved benefits both in PFS and OS.
Conclusions
PD-1 blockade plus chemotherapy showed superior efficacy than PD-1 blockade monotherapy or chemotherapy alone in patients with oncogenic-driven advanced NSCLC, particularly in KRAS, EGFR and BRAF subgroup, indicating that PD-1 blockade plus chemotherapy could be considered as optional treatments when these patients without available targeted therapy.
Legal entity responsible for the study
The authors.
Funding
This study was supported in part by grants from the National Natural Science Foundation of China (Nos.82102859, 82172869, 82141101, 82272875 and 12126605).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract